AstraZeneca’s Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The company has “received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg,” AstraZeneca Pharma India said in a filing to BSE., The company has “received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg,” AstraZeneca Pharma India said in a filing to BSE., , Read More